Your browser doesn't support javascript.
loading
A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
Sánchez-Hernández, José Germán; Rebollo, Noemí; Martin-Suarez, Ana; Calvo, M Victoria; Muñoz, Fernando.
Affiliation
  • Sánchez-Hernández JG; Pharmacy Service, University Hospital of Salamanca, Spain.
  • Rebollo N; Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain.
  • Martin-Suarez A; Biomedical Research Institute of Salamanca (IBSAL), Spain.
  • Calvo MV; Pharmacy Service, University Hospital of Salamanca, Spain.
  • Muñoz F; Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain.
Br J Clin Pharmacol ; 86(6): 1165-1175, 2020 06.
Article in En | MEDLINE | ID: mdl-32022291
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Drug Monitoring Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2020 Document type: Article Affiliation country: Spain
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Drug Monitoring Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2020 Document type: Article Affiliation country: Spain